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Maternal smoking during pregnancy is a 
major risk factor for adverse health outcomes 
in children including low birth weight, some 
childhood cancers, reduced lung function, 
and early respiratory illnesses (Office of the 
Surgeon General 2006). Recent evidence sug-
gests that maternal smoking during pregnancy 
leads to obesity and elevated blood pressure 
in children (Brion et al. 2008; Cupul-Uicab 
et al. 2012). The underlying mechanisms for 
the diverse effects of maternal smoking during 
pregnancy on offspring may involve epigenetic 
modifications such as DNA methyla tion.
DNA cytosine methyla tion plays a key role 
in modulating the transcriptional potential of 
the genome and may influence the develop-
ment of complex human diseases (Feinberg 
2010). Changes to DNA methyla tion can 
occur throughout life, but much of the epige-
nome is established during embryogenesis and 
early development of the fetus (Reik 2007).
Data from animal models demonstrate 
that maternal exposures, such as dietary 
methyl donors (Hollingsworth et al. 2008) 
and bisphenol A (Dolinoy et al. 2007), 
can affect offspring phenotypes via DNA 
methylation. A few human studies have 
examined epigenetic alterations in relation 
to maternal smoking during pregnancy 
and reported it to be associated with global 
methyla tion of leukocyte DNA using a [3H]-
methyl accept ance assay (Terry et al. 2008), 
global [LINE-1 (long interspersed nuclear 
element-1) and AluYb8 (short interspersed 
element)] methyla tion in human placenta 
(Wilhelm-Benartzi et al. 2012), or differential 
methyla tion at cytosine–guanine dinucleotide 
(CpG) sites [CpG-specific methyla tion using 
the Illumina Infinium HumanMethyla tion27 
Beadchip (27K) (Illumina Inc., San Diego, 
CA, USA) measuring approximately 27,000 
CpGs] in human placenta (Suter et al. 2011). 
Maternal tobacco use during pregnancy has 
also been associated with global (LINE-1 
and AluYb8) and CpG-specific methyla tion 
(Illumina GoldenGate Cancer methyla tion 
panel I measuring 1,505 CpGs) in buccal cells 
from children (Breton et al. 2009). To date, 
the effect of maternal smoking on differential 
DNA methyla tion has not been evaluated with 
more comprehensive epigenomic coverage 
than offered by the 27K platform. Using the 
Infinium HumanMethyla tion450 Beadchip 
(450K; Illumina Inc.), which measures CpG 
methyla tion at > 470,000 CpGs, we evaluated 
the relationship between maternal smoking 
and DNA methyla tion in 1,062 infant cord 
blood samples from a birth cohort in Norway. 
We assessed maternal smoking objectively by 
measuring cotinine, a sensitive biomarker, in 
maternal plasma samples, and replicated our 
findings in an independent birth cohort study 
from the U.S. To our knowledge, this is the 
largest human study of any in utero exposure 
in relation to DNA methyla tion at birth using 
the 450K platform with improved epigenome-
wide coverage.
Methods
Participants in the current analysis were 
selected from a substudy of the Norwegian 
Mother and Child Cohort Study (MoBa) 
(Magnus et al. 2006; Ronningen et al. 2006) 
that evaluated the association between maternal 
plasma folate during pregnancy and childhood 
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Background: Epigenetic modifications, such as DNA methyla tion, due to in utero exposures may 
play a critical role in early programming for childhood and adult illness. Maternal smoking is a 
major risk factor for multiple adverse health outcomes in children, but the underlying mechanisms 
are unclear.
oBjective: We investigated epigenome-wide methyla tion in cord blood of newborns in relation to 
maternal smoking during pregnancy.
Methods: We examined maternal plasma cotinine (an objective biomarker of smoking) measured 
during pregnancy in relation to DNA methyla tion at 473,844 CpG sites (CpGs) in 1,062 new-
born cord blood samples from the Norwegian Mother and Child Cohort Study (MoBa) using the 
Infinium HumanMethyla tion450 BeadChip (450K).
results: We found differential DNA methyla tion at epigenome-wide statistical significance 
(p-value < 1.06 × 10–7) for 26 CpGs mapped to 10 genes. We replicated findings for CpGs in 
AHRR, CYP1A1, and GFI1 at strict Bonferroni-corrected statistical significance in a U.S. birth 
cohort. AHRR and CYP1A1 play a key role in the aryl hydrocarbon receptor signaling pathway, 
which mediates the detoxification of the components of tobacco smoke. GFI1 is involved in diverse 
developmental processes but has not previously been implicated in responses to tobacco smoke.
conclusions: We identified a set of genes with methyla tion changes present at birth in children 
whose mothers smoked during pregnancy. This is the first study of differential methyla tion across 
the genome in relation to maternal smoking during pregnancy using the 450K platform. Our find-
ings implicate epigenetic mechanisms in the pathogenesis of the adverse health outcomes associated 
with this important in utero exposure.
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asthma status at 3 years of age (Håberg et al. 
2011). We analyzed 1,062 participants of this 
study who had available cord blood samples 
and nonmissing data for maternal cotinine and 
covariates. Umbilical cord blood samples were 
collected at birth and frozen at –80°C. All bio-
logical material was obtained from the biobank 
of the MoBa study (Ronningen et al. 2006). 
The MoBa study has been approved by the 
Regional Committee for Ethics in Medical 
Research, the Norwegian Data Inspectorate, 
and the Institutional Review Board of the 
National Institute of Environmental Health 
Sciences, and written informed consent was 
provided by all participants. Participants in 
the replication analysis were part of the 
Newborn Epigenetics Study (NEST) and were 
recruited from prenatal clinics in Durham, 
North Carolina (Hoyo et al. 2011; Murphy 
et al. 2012). We selected cord blood DNA 
samples from 18 newborns born to moth-
ers who reported smoking during pregnancy 
and 18 whose mothers reported no smoking, 
all Caucasians. The NEST study has been 
approved by the Duke University Institutional 
Review Board, and written informed consent 
was provided by all participants.
Bisulfite conversion was performed using 
the EZ-96 (MoBa samples) or EZ (NEST sam-
ples) DNA Methyla tion kit (Zymo Research 
Corporation, Irvine, CA) according to manu-
facturer instructions. We measured methyla-
tion at 485,577 CpGs in cord blood using 
Illumina’s Infinium HumanMethyla tion450 
BeadChip (Bibikova et al. 2011; Sandoval et al. 
2011). Illumina’s GenomeStudio® Methyla tion 
module version 1.0 (Illumina Inc.) was used to 
calculate the methyla tion level at each CpG as 
the beta-value [β = intensity of the methylated 
allele (M) / (intensity of the unmethylated 
allele (U) + intensity of the methylated allele 
(M) + 100)] (Bibikova et al. 2011). Beta-values 
were then transformed to obtain the log ratio, 
defined as log[β/(1 – β)]. We report the detec-
tion p-value for each beta, which represents a 
statistical test for the difference between the 
signal for a given probe and background (the 
average for all negative controls).
Maternal plasma cotinine concentrations 
in the MoBa samples were measured using liq-
uid chromatography–tandem mass spectrom-
etry (Midttun et al. 2009). With guidance 
from a previous study with data on circulat-
ing cotinine in pregnant women (Shaw et al. 
2009), we created four categories of exposure 
(undetectable: ≤ 0 nmol/L; low: > 0–56.8 
nmol/L; moderate: > 56.8–388 nmol/L; high: 
> 388 nmol/L), where 56.8 nmol/L indicates 
active maternal smoking and participants with 
levels > 56.8 nmol/L were categorized at the 
median value for this group (388 nmol/L). 
Smoking in the NEST samples was assessed 
by maternal self-report of smoking during 
pregnancy and verified by medical records.
Quality control protocols are described 
in detail in Supplemental Material, pp. 3–5 
(http://dx.doi.org/10.1289/ehp.1205412). 
After quality control, 1,062 MoBa subjects 
and 473,844 CpGs were analyzed. We exam-
ined the association between maternal plasma 
cotinine and methyla tion in cord blood at each 
CpG using robust linear regression to account 
for any potential outliers or hetero skedasticity 
in the data (Fox and Weisberg 2011). We 
evaluated maternal age (continuous vari-
able), maternal education (< high school, high 
school, some college, and ≥ 4 years of college 
as the referent group), maternal pre-pregnancy 
body mass index (< 18.5, 18.5 to < 25, 25 to 
< 30, ≥ 30), maternal physical activity during 
pregnancy (none, moderate, vigorous), mater-
nal plasma folate (log-transformed continuous 
variable), parity (0 as the referent group, 1, 
2, and ≥ 3), and sex of the child for associa-
tions with maternal plasma cotinine. The final 
model included variables that were associated 
with cotinine (p < 0.1) and plausibly related 
to methyla tion levels, specifically maternal 
age, maternal education, and parity. Because 
our study was a subset of that of Håberg et al. 
(2011), where cotinine was measured among 
asthmatic children in a later analytic batch, we 
adjusted for childhood asthma status at 3 years 
of age although this made little difference in the 
results. Overall, the crude and adjusted results 
were extremely similar. We applied Bonferroni 
correction, adjusting the level of significance 
from 0.05 to 1.06 × 10–7. Additional adjust-
ment for principal components to address 
potential population structure (Rakyan et al. 
2011) was explored but not retained because it 
did not influence the results.
All NEST samples and CpGs passed 
quality control. We used unadjusted linear 
regression models to examine the association 
between maternal smoking during pregnancy 
and methyla tion in cord blood at each of the 
26 CpGs that were significantly associated 
with plasma cotinine (p < 1.06 × 10–7) in 
the MoBa population, and we calculated a 
one-sided p-value for each CpG. We applied 
Bonferroni correction for 26 tests, which 
adjusted the level of significance to 0.0019. 
We used the Kolmogorov test to test the null 
hypothesis that the p-values are uniformly dis-
tributed on (0,1) against the alternative that 
the p-values were stochastically smaller than 
uniform distribution on (0,1). Because CpGs 
corresponding to the same gene may not be 
independent, and because some genes were 
represented by multiple CpGs, for such genes 
we chose the CpG that had the largest p-value 
when using the Kolmogorov test, thus making 
the Kolmogorov test more conservative against 
the alternative hypothesis.
To assess the potential impact of variation 
according to white blood cell subtype, we 
measured DNA methyla tion using the 450K 
platform in 21 cord blood samples collected 
at the same facilities as the NEST samples that 
had been separated while fresh into mononu-
clear cells (MN) and polymorphonuclear cells 
(PM) using Lympholyte®-poly (Cedarlane 
Laboratories Limited, Hornby, Ontario). We 
used a paired t-test to evaluate differential 
methyla tion between PM and MN cell types 
for our top 26 CpGs.
To compare our results with those from 
other studies, we employed a single CpG 
lookup approach where we looked at the result 
in our data for the CpG of interest and did 
not correct for multiple comparisons. A CpG 
with a p-value < 0.05 was considered to be sta-
tistically significant. All statistical analyses were 
performed using R (R Development Core 
Team 2010) and Bioconductor (Gentleman 
et al. 2004) packages.
Results
Epigenome-wide analysis. We plotted the 
–log10(p-values) from the robust linear regres-
sion for 473,844 CpGs across the genome in 
1,062 cord blood samples of participants in 
the MoBa study (Figure 1). The mean (± SD) 
age of study participants was 29.5 ± 4.3 years, 
12.8% had plasma cotinine levels consistent 
with active smoking (Shaw et al. 2009), and 
11.7% reported current smoking during preg-
nancy (Table 1). The methyla tion intensities 
showed bimodal distribution when displayed 
across all probes [see Supplemental Material, 
Figure S1A,B for beta and log-ratio values, 
respectively (http://dx.doi.org/10.1289/
ehp.1205412)] but approximately normal 
distribution for most CpGs when they were 
considered individually (see Supplemental 
Material, Figure S1C,D).
Using conservative Bonferroni correction 
for 473,844 tests, we observed epigenome-wide 
statistically significant associations (p-value 
< 1.06 × 10–7) between maternal plasma coti-
nine and DNA methyla tion for 26 CpGs 
mapped to 10 genes in both unadjusted and 
covariate-adjusted analyses (Figure 1, Table 2). 
Four genes included at least four Bonferroni-
significant CpGs. Among the 26 CpGs, 8 were 
within the coding region of growth factor inde-
pendent 1 transcription repressor (GFI1) on 
chromosome 1; 4 were within the coding region 
of aryl-hydrocarbon receptor repressor (AHRR) 
on chromosome 5; 4 were in a region upstream 
of cytochrome P450 isoform CYP1A1 on chro-
mosome 15; and 4 were within the  coding 
region of myosin 1G (MYO1G).
Methyla tion levels of AHRR cg05575921, 
the CpG with the smallest p-value in the 
analysis, decreased with cotinine in a dose-
dependent manner, and the trend was statisti-
cally significant [see Supplemental Material, 
Figure S2, Jonkheere–Terpstra trend test 
p < 2.2 × 10–16 (http://dx.doi.org/10.1289/
ehp.1205412)]. All other statistically 
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significant AHRR CpGs (see Supplemental 
Material, Figure S3A) had lower methyla-
tion with increasing cotinine levels except 
for cg23067299, which is upstream of the 
other significant AHRR CpGs and had higher 
methyla tion with increasing cotinine (see 
Supplemental Material, Table S1). Conversely, 
CYP1A1 cg05549655 (p = 2.38 × 10–10) and 
other statistically significant CYP1A1 CpGs 
(see Supplemental Material, Figure S3B), 
had higher methyla tion with increasing lev-
els of cotinine. As with AHRR, cotinine was 
inversely related to methyla tion for GFI1 
cg09935388 (p = 2.68 × 10–31) and other 
statistically significant GFI1 CpGs. All four 
statistically significant CpGs in MYO1G had 
higher methyla tion with increasing levels of 
cotinine (Table 2). Other genes in which 
methyla tion was associated with cotinine 
levels at epigenome-wide statistical signifi-
cance are HLA-DPB2, ENSG00000225718, 
TTC7B, CNTNAP2, EXT1, and RUNX1 
(Table 2). Coefficients, p-values, locations, 
and other information for the 100 most sta-
tistically significant CpGs are provided in 
Supplemental Material Table S1.
We obtained similar DNA methyla tion 
differences when the metric of exposure was 
maternal self-report of smoking during preg-
nancy rather than measured maternal coti-
nine levels. Specifically, self-reported maternal 
smoking was related to lower methyla tion 
of AHRR CpGs cg03991871, cg05575921, 
and cg21161138, with similar regression 
coefficients as in the cotinine analysis, and 
was epigenome-wide statistically signifi-
cant for cg05575921 [regression coefficient 
(coef) = –0.131, SE = 0.017, p = 2.40× 10–15]. 
Self-reported maternal smoking was associ-
ated with higher methyla tion of the CYP1A1 
CpGs shown in Table 2 but did not achieve 
epigenome-wide statistical significance (e.g., 
cg05549655: coef = 0.039, SE = 0.010, 
p = 1.72 × 10–4). Self-reported maternal 
smoking was associated with epigenome-wide 
statistically significant lower methyla tion of 
seven of the eight GFI1 CpGs that had sig-
nificant (p < 1.06 × 10–7) inverse associations 
with maternal cotinine. Higher methyla tion 
of the four MYO1G CpGs statistically signifi-
cantly associated with maternal cotinine was 
observed with maternal smoking but did not 
reach epigenome-wide statistical significance.
Replication analysis. All twenty-six CpGs 
showing epigenome-wide statistical signifi-
cance for the association between plasma coti-
nine and methyla tion in MoBa were followed 
up for replication analysis in cord blood 
DNA samples from offspring of 18 mothers 
who reported smoking during pregnancy and 
18 mothers who denied smoking during preg-
nancy from the NEST study (Table 3). The 
direction of effect (differential methyla tion 
by smoking status) in the NEST replication 
study was consistent with the discovery study 
(MoBa) for all 26 CpGs, and the magnitudes 
of the differences between smokers and non-
smokers in NEST and those between women 
with plasma cotinine > 56.8 nmol/L versus 
≤ 56.8 nmol/L in MoBa were very similar 
(Table 3, Figure 2, Spearman’s correlation 
coefficient = 0.965). The most statistically sig-
nificant association in both MoBa and NEST 
data was observed for AHRR cg05575921 
with lower methyla tion for smokers com-
pared with nonsmokers (Table 3). In the 
NEST study, a total of five CpGs (AHRR 
cg05575921, CYP1A1 cg05549655 and 
cg11924019, and GFI1 cg09935388 and 
cg12876356) reached statistical significance 
after strict Bonferroni correction for 26 tests 
(p < 0.0019), despite the much smaller sam-
ple size of the replication study (18 newborns 
of smoking mothers compared with 18 new-
borns of nonsmoking mothers), and a total 
of 21 of the 26 CpGs gave a p-value < 0.05 
(Table 3). The Kolmogorov test showed that 
the replication p-values were systematically 
smaller than would be expected by chance 
(p < 0.00011). This suggests that it is exceed-
ingly unlikely that the replication findings are 
false positives and confirms the high degree of 
replication that we observed.
The magnitudes of the differences in 
methyla tion between PM and MN cell types 
(Table S2) were much smaller than the differ-
ences in methyla tion between smokers and non-
smokers in both the MoBa and NEST study 
populations (Table 3) and were not statistically 
Figure 1. Epigenome-wide association between maternal cotinine and methyla tion of 473,844 CpGs 
 measured in cord blood from the MoBa cohort. Twenty-six CpGs (10 genes) reached Bonferroni-corrected 
statistical significance (p < 1.06 × 10–7, represented by the horizontal line). Red and blue alternating colors 




















Physical location (by chromosome)
1 2 3 4 5 6 7 8 9 11 13 15 17 20
Table 1. Descriptive characteristics of the MoBa 
study population (n = 1,062).
Characteristic n (%)
Maternal cotinine (nmol/L)a
Undetectable (0) 736 (69.3) 
Low (> 0–56.8) 190 (17.9) 
Moderate (> 56.8–388) 68 (6.4) 
High (> 388) 68 (6.4)
Self-reported maternal smoking
Never 525 (49.4) 
Former (stopped before pregnancy) 233 (21.9) 
Stopped during pregnancy 180 (16.9) 





< High school 78 (7.3) 
High school 343 (32.3) 
Some college 471 (44.4) 
≥ 4 years of college 170 (16.0) 
Parity
0 447 (42.1) 
1 435 (41.0) 
2 137 (12.9) 
≥ 3 43 (4.0)
aMaternal cotinine measured in plasma at approximately 
gestational week 18. Cotinine values > 56.8 nmol/L are 
consistent with active smoking.
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significantly different between cell types (using 
p < 0.0019 after Bonferroni correction for 26 
tests) for the 5 replicated CpGs.
Discussion
Our study of maternal smoking in relation to 
epigenome-wide DNA methyla tion in new-
borns in the MoBa cohort is the largest and 
most extensive that we know of. In addition to 
the large sample size, we used a highly repro-
ducible platform that assesses methyla tion at 
> 470,000 individual CpGs, providing more 
comprehensive coverage of the epigenome than 
other studies of maternal smoking published 
to date. Further, we assessed maternal smok-
ing with a sensitive assay for cotinine, a well-
validated biomarker for tobacco smoke. We 
observed epigenome-wide statistically signifi-
cant associations between maternal smoking in 
pregnancy, assessed by plasma cotinine levels 
and methyla tion in cord blood at 26 CpGs 
mapping to 10 genes in MoBa. In an inde-
pendent birth cohort from the United States, 
the NEST study, we found a striking degree 
of replication for our findings. In the NEST 
replication population, the direction of dif-
ferential methyla tion in relation to maternal 
smoking was consistent with the direction 
in relation to maternal plasma cotinine 
for all of the 26 CpGs that were significant 
(p < 1.06 × 10–7) in the discovery study. In 
addition, despite the more modest sample size 
of the replication set (18 newborns born to 
smoking mothers and 18 born to nonsmok-
ers), estimates for 21 of 26 CpGs had p-val-
ues < 0.05. Five CpGs of the 26 met strict 
Bonferroni-corrected statistical significance 
in the replication study (p < 0.0019): two in 
CYP1A1 and one in AHRR, genes known to be 
involved in the detoxification of compounds 
from tobacco smoke via the aryl hydrocarbon 
receptor (AhR) signaling pathway; and two 
CpGs in GFI1, a gene that has not previously 
been implicated in responses to tobacco smoke.
Our most statistically significant finding 
in both the replication and discovery analyses 
was lower methyla tion with higher levels of 
self-reported or cotinine-based evidence of 
maternal smoking at cg05575921 in AHRR. 
Remarkably, a recent study in adults, using 
the same 450K platform, showed lower 
methyla tion at this same CpG (cg05575921) 
in smokers compared with nonsmokers at 
epigenome-wide statistical significance 
(Monick et al. 2012). That study observed 
lower methyla tion in smokers at this CpG 
for both lymphoblasts and pulmonary alveo-
lar macrophages (Monick et al. 2012). The 
authors also studied the functional implica-
tions of this methyla tion change and found 
that methyla tion at AHRR cg05575921 was 
associated with AHRR expression. Thus our 
data show that a methyla tion change found in 
adult smokers and implicated as functionally 
important in AHRR, a gene involved in a key 
pathway of response to tobacco smoke com-
ponents, is already present at birth in new-
borns due to maternal smoking in pregnancy.
Our findings for genes in the AhR path-
way make sense biologically; the pathway is 
known to mediate the effects of toxicants such 
as polycyclic aromatic hydrocarbons (PAH) in 
tobacco smoke. PAH bind to AhR causing its 
translocation to the nucleus and the formation 
of a heterodimer with the AhR nuclear trans-
porter. This complex binds DNA regulatory 
sequences, termed xenobiotic response elements 
(XREs), and initiates the expression of CYP1A1 
and other genes involved in detoxification of 
these chemicals (Nguyen and Bradfield 2008). 
The AhR repressor (AHRR) acts as a negative 
regulator of AhR activity, suppressing CYP1A1 
transcription (Harper et al. 2006). In our 
study, maternal smoking, assessed objectively 
by cotinine, displayed a dose-dependent asso-
ciation with lower methyla tion of AHRR CpGs 
and higher methyla tion of CYP1A1 CpGs in 
cord blood. The contrasting effects of maternal 
smoking during pregnancy on methyla tion 
at CpGs in AHRR and CYP1A1 are notable 
because of the opposing function these genes 
have in the AhR pathway (Kawajiri and Fujii-
Kuriyama 2007).
Although the role of the AhR pathway in 
response to toxicants is well known, there is 
increasing identification of the importance of 
Table 2. Differential methyla tion in cord blood DNA in relation to maternal cotinine in the MoBa study population: CpGs with Bonferroni-corrected statistical 




Median methyla tion  
by cotinine categoryh
Chra Gene CpG Positionc Coefd SEe p-Value Coef SE p-Value Rankg Undetectable Low Medium High
1 GFI1 3688 cg10399789 92945668 –0.07 0.01 4.08E-13 –0.065 0.010 1.10E-10 14 0.759 0.755 0.727 0.716
1 GFI1 3224 cg09662411 92946132 –0.111 0.012 2.26E-20 –0.106 0.013 2.96E-17 11 0.730 0.733 0.669 0.654
1 GFI1 3169 cg06338710 92946187 –0.112 0.013 1.34E-18 –0.106 0.014 5.02E-14 12 0.801 0.800 0.754 0.733
1 GFI1 2656 cg18146737 92946700 –0.28 0.024 2.42E-30 –0.271 0.026 3.30E-25 6 0.877 0.875 0.771 0.738
1 GFI1 2531 cg12876356 92946825 –0.182 0.016 2.29E-30 –0.176 0.017 1.70E-25 4 0.731 0.732 0.627 0.605
1 GFI1 2321 cg18316974 92947035 –0.243 0.024 6.43E-24 –0.238 0.026 3.16E-20 7 0.921 0.923 0.856 0.841
1 GFI1 1768 cg09935388 92947588 –0.196 0.015 1.05E-38 –0.188 0.016 2.68E-31 2 0.708 0.707 0.580 0.564
1 GFI1 1395 cg14179389 92947961 –0.184 0.017 5.38E-28 –0.181 0.017 2.63E-25 5 0.242 0.246 0.154 0.158
5 AHRR 19617 cg23067299 323907 0.075 0.012 4.21E-10 0.072 0.012 4.12E-09 20 0.789 0.789 0.813 0.837
5 AHRR 64157 cg03991871 368447 –0.057 0.008 2.04E-11 –0.054 0.009 1.99E-10 15 0.841 0.839 0.820 0.818
5 AHRR 69088 cg05575921 373378 –0.202 0.015 2.85E-39 –0.198 0.017 8.03E-33 1 0.883 0.874 0.829 0.784
5 AHRR 95070 cg21161138 399360 –0.045 0.007 1.52E-11 –0.043 0.007 8.91E-10 18 0.718 0.715 0.701 0.679
6 HLA-DPB2 11549 cg11715943 33091841 –0.053 0.009 1.00E-08 –0.054 0.010 3.63E-08 23 0.842 0.833 0.824 0.820
7 MYO1G 16417 cg19089201 45002287 0.083 0.013 3.22E-10 0.088 0.014 9.13E-11 13 0.925 0.926 0.932 0.944
7 MYO1G 16218 cg22132788 45002486 0.18 0.021 1.98E-18 0.184 0.021 4.82E-18 10 0.932 0.935 0.951 0.966
7 MYO1G 15968 cg04180046 45002736 0.073 0.008 8.76E-20 0.076 0.008 2.85E-19 9 0.441 0.446 0.484 0.508
7 MYO1G 15785 cg12803068 45002919 0.145 0.016 8.51E-19 0.149 0.016 1.25E-19 8 0.713 0.721 0.774 0.813
7 ENSG00000225718 198306 cg04598670 68697651 –0.063 0.009 1.29E-11 –0.061 0.010 1.27E-09 19 0.623 0.607 0.597 0.574
7 CNTNAP2 854 cg25949550 145814306 –0.075 0.007 4.15E-30 –0.073 0.007 1.02E-26 3 0.113 0.109 0.097 0.092
8 EXT1 –33821 cg03346806 119157879 –0.038 0.007 3.08E-08 –0.039 0.007 9.34E-08 26 0.801 0.795 0.793 0.779
14 TTC7B 274756 cg18655025 91008005 –0.041 0.007 2.07E-08 –0.042 0.008 6.76E-08 25 0.854 0.847 0.841 0.836
15 CYP1A1 –1266 cg05549655 75019143 0.064 0.01 2.96E-10 0.065 0.010 2.38E-10 16 0.189 0.188 0.221 0.226
15 CYP1A1 –1374 cg22549041 75019251 0.096 0.016 4.52E-09 0.098 0.017 8.88E-09 21 0.385 0.379 0.414 0.475
15 CYP1A1 –1406 cg11924019 75019283 0.044 0.008 2.62E-08 0.044 0.008 4.78E-08 24 0.434 0.430 0.457 0.475
15 CYP1A1 –1425 cg18092474 75019302 0.066 0.012 1.10E-08 0.068 0.012 9.95E-09 22 0.510 0.504 0.549 0.573
21 RUNX1 1746 cg12477880 36259241 0.159 0.026 1.02E-09 0.163 0.026 7.55E-10 17 0.088 0.102 0.110 0.158
aChromosome. bDistance from CpG to transcription start site of the nearest gene. cChromosomal position based on NCBI human reference genome assembly Build 37.3. dRegression 
coefficient. eStandard error for regression coefficient. fAdjusted for maternal age, maternal education, parity, and asthma. gRank order based on the adjusted p-value. hMaternal 
plasma cotinine (nmol/L) measured around gestational week 18 (undetectable: ≤ 0; low: > 0–56.8; moderate: > 56.8–388; high: > 388). Values > 56.8 nmol/L indicate active smoking.
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this pathway in the regulation of other pro-
cesses, such as immune function (Lawrence 
and Sherr 2012). In addition, AhR has also 
recently been found to play a crucial role in 
regulating cigarette smoke extract–induced 
apoptosis in fibroblasts (lung and embryonic) 
and lung epithelial cells in culture from the 
mouse (Rico de Souza et al. 2011).
We also replicated our novel findings for 
GFI1, which has not previously been impli-
cated in response to tobacco smoke. GFI1 
plays an essential role in diverse develop-
mental processes including hematopoiesis 
and the development of the inner ear and 
pulmonary neuroendocrine cells (Duan et al. 
2005; Khandanpour et al. 2011). GFI1 influ-
ences numerous cellular events such as pro-
liferation, apoptosis, differentiation, lineage 
decisions, and oncogenesis (Jafar-Nejad and 
Bellen 2004). This gene is part of a complex 
that enables histone modifications and may 
also control alternative pre-mRNA splicing 
(Moroy and Khandanpour 2011). Given the 
pivotal involvement of GFI1 in fundamen-
tal development processes, a role in diverse 
effects of maternal smoking on the offspring 
is biologically plausible.
Although our findings for RUNX1 did 
not meet strict Bonferroni statistical signifi-
cance in the replication population (NEST 
p > 0.00019), there were four RUNX1 CpGs 
in the top 100 results in the MoBa discov-
ery population [see Supplemental Material, 
Table S1 (http://dx.doi.org/10.1289/
ehp.1205412)]. RUNX1 (also known as 
AML1) is involved in the development of 
normal hematopoiesis as well as leukemia 
(Kumano and Kurokawa 2010). Of note, 
RUNX1, AhR, and GFI1 are all involved in 
the regulation of hematopoietic stem cells 
(Boitano et al. 2010; Khandanpour et al. 
2011; Oshima et al. 2011), suggesting the 
possibility that cross-talk between these genes 
may impact smoking-related health outcomes 
in the offspring.
Correlation of DNA methyla tion at 
CpGs within the same gene may contribute 
to the finding of genes with multiple signifi-
cant CpGs in our analyses. However, if CpGs 
are not truly independent, then using strict 
Bonferroni correction for multiple testing, 
which assumes independent tests, is quite 
conservative. This adds support for the results 
that surpassed this strict threshold, partic-
ularly the five CpGs with corrected statis-
tical significance in both the discovery and 
 replication populations.
Cotinine, the biomarker of smoking, was 
not measured among pregnant women in the 
replication (NEST) study, so we used mater-
nal self-report of smoking on questionnaires 
that was consistent with medical records 
of smoking. Among our MoBa study par-
ticipants, 8 of the 136 women (5.9%) with 
cotinine values consistent with active smoking 
(≥ 56.8 nmol/L) reported that they did not 
smoke during pregnancy. A study of U.S. 
reproductive age women using NHANES 
(National Health and Nutrition Examination 
Survey) data indicates that U.S. pregnant 
women also underreport smoking (Dietz 
et al. 2011). Thus, we expect that some of the 
NEST participants classified as nonsmokers 
might actually have been smokers. However, 
this type of misclassification should lead to a 
bias of estimates toward the null, making our 
replication estimates more conservative than 
would be expected if smokers had reported 
their exposure with 100% accuracy.
The 450K Beadchip offers greatly improved 
genomic coverage over the earlier 27K plat-
form. The 450K content includes 99% of 
Figure 2. Difference in median methyla tion intensity (β) by smoking status among MoBa and NEST partici-

































































































































































































































































Table 3. Replication results from the NEST cohort for the 26 CpGs reaching epigenome-wide Bonferroni-
corrected statistical significance (p < 1.06 × 10–7) in the MoBa cohort, and median methyla tion differ-
ences by maternal smoking for MoBa and NEST cohorts, sorted by NEST p-value.
NEST 
p-valuea
Percent difference in 
median methyla tion 
(smokers – nonsmokers)
Chromosome Gene CpG MoBab NESTc
5 AHRR cg05575921 0.0003* –7.5 –7.7
15 CYP1A1 cg05549655 0.0006* 3.5 3.8
15 CYP1A1 cg11924019 0.0008* 3.2 5.3
1 GFI1 cg09935388 0.0012* –13.7 –7.5
1 GFI1 cg12876356 0.0015* –11.9 –10.5
1 GFI1 cg18316974 0.0023 –7.1 –9.0
1 GFI1 cg09662411 0.0023 –6.6 –6.8
7 CNTNAP2 cg25949550 0.0025 –1.8 –2.5
1 GFI1 cg06338710 0.0026 –5.8 –5.2
7 MYO1G cg04180046 0.0027 5.3 4.9
7 ENSG00000225718 cg04598670 0.0036 –3.0 –5.3
5 AHRR cg23067299 0.0036 3.2 3.7
1 GFI1 cg18146737 0.0037 –12.3 –15.1
7 MYO1G cg12803068 0.0041 8.3 3.8
1 GFI1 cg14179389 0.0043 –8.6 –8.2
15 CYP1A1 cg22549041 0.0044 7.2 8.9
15 CYP1A1 cg18092474 0.0044 5.9 5.3
7 MYO1G cg19089201 0.0092 1.4 2.2
7 MYO1G cg22132788 0.0096 2.8 2.1
1 GFI1 cg10399789 0.0154 –3.7 –3.4
5 AHRR cg21161138 0.0283 –2.3 –1.7
5 AHRR cg03991871 0.0655 –2.2 –2.3
21 RUNX1 cg12477880 0.0850 4.6 4.0
8 EXT1 cg03346806 0.1248 –1.5 –0.1
14 TTC7B cg18655025 0.2668 –1.2 –1.1
6 HLA-DPB2 cg11715943 0.7956 –1.8 –0.3
ap-Value from NEST replication linear regression model evaluating differential DNA methyla tion by maternal smoking 
during pregnancy. bMoBa maternal smoking status determined by gestational week 18 cotinine values > 56.8 nmol/L 
(smoker) or ≤ 56.8 nmol/L (nonsmoker). cNEST maternal smoking status determined by maternal self-report, verified by 
medical records. *Bonferroni-corrected statistically significant (p < 0.0019).
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RefSeq genes with multiple probes per gene, 
96% of CpG islands from the UCSC database 
(http://genome.ucsc.edu/), CpG island shores, 
and additional content selected from whole-
genome bisulfite sequencing data and input 
from DNA methyla tion experts (Bibikova et al. 
2011). None of the 26 CpGs with epigenome-
wide significance in our study were present on 
the 27K platform. A study using the 27K plat-
form observed differences in DNA methyla-
tion associated with smoking status in adults 
at CpG cg03636183 in F2RL3, a gene asso-
ciated with cardiovascular disease (Breitling 
et al. 2011). Employing a single CpG look-up 
approach (one CpG evaluated, uncorrected 
for multiple testing), our data provide sup-
port for an association between maternal 
smoking during pregnancy and cord blood 
DNA methyla tion at this CpG (coef = –0.020, 
se = 0.009, p = 0.016). Another recent study 
of 27K methyla tion and adult smoking identi-
fied cg19859270 in GPR15 (Wan et al. 2012). 
Our single look-up approach for this CpG did 
not provide supporting results (coef = –0.010, 
SE = 0.007, p = 0.181).
Maternal smoking during pregnancy has 
been associated with CpG-specific differential 
DNA methyla tion in placental tissue using 
the 27K Beadchip (Suter et al. 2011), but we 
found no overlap between the top hits from 
that study and the top hits in our study using 
the 450K Beadchip to measure methyla tion 
in newborn cord blood samples. In addition 
to the limitations of comparing the 27K and 
450K platforms (the top 26 CpGs from our 
study were not covered on the 27K platform), 
it is likely that altered methyla tion in response 
to tobacco smoke exposure is different in pla-
cental tissue and newborn cord blood.
We measured DNA methyla tion in whole 
cord blood samples. Because hematopoietic dif-
ferentiation and methyla tion status of differ-
entially methylated regions (DMRs) are highly 
coordinated (Schmidl et al. 2009), significant 
shifts in cell type pools in the blood should be 
accompanied by shifts in methyla tion at dozens, 
if not hundreds, of cell type–specific DMRs. If 
our findings were simply a reflection of mater-
nal smoking influencing shifts in cell types, 
we would expect to find many differentially 
methyla ted genes, which we did not. Instead, 
only 10 genes had differences in methyla tion 
levels related to cotinine in our data.
Notably, the recent paper of Monick et al. 
(2012) supports the notion that unmeasured 
confounding by cell type does not explain the 
altered methyla tion status that we observed in 
relation to smoking. In that paper, smoking-
induced alteration of AHRR CpGs (including 
our top CpG) was seen in both B lympho-
blastoid cells and in an independently col-
lected sample of alveolar macrophage cells 
collected from bronchial lavage. Thus, Monick 
et al. identified smoking-induced signals across 
two distinct cell types, which strengthens our 
 replicated whole blood findings.
Although the above evidence suggests that 
our results are not confounded by cell type, we 
directly addressed the potential impact of differ-
ential cell counts by measuring epigenome-wide 
DNA methyla tion, using the 450K assay, in 
21 cord blood samples that had been separated, 
while fresh, into the two major cell pools, PM 
cells and MN cells. In these 21 paired samples 
differences in methyla tion by cell type were 
very small. These small differences were sta-
tistically significant (p < 0.0019) for 3 of the 
top 26 CpGs associated with maternal plasma 
cotinine in MoBa, but these CpGs were not 
significantly associated with maternal smoking 
in the NEST population. Furthermore, the 
magnitude of the difference in median methyla-
tion between PM and MN cell types was much 
smaller than the difference in median methyla-
tion between smokers and nonsmokers in both 
the MoBa and NEST study populations. For 
the percent difference in median methyla tion 
by cell type, the maximum was 3.1% and the 
mean was 1.0%. In contrast, for the percent dif-
ference in median methyla tion between smok-
ers and non-smokers measured in whole blood, 
which is a mixture of these two major cell types 
(PM and MN), the maximum was 13.7% 
(MoBa) and 15.1% (NEST), and the mean 
was 5.3% (MoBa) and 5.0% (NEST). For our 
top CpG AHRR cg05575921, the percent dif-
ference in median methyla tion was 0.31% by 
cell type compared with 7.52% for smokers 
compared with nonsmokers in MoBa (7.67% 
in NEST). Thus, the differences in methyla tion 
between these two major cell pools are much 
smaller than the differences in methyla tion by 
smoking that we observed in whole blood, sug-
gesting that confounding by cell type is unlikely 
to explain our findings of differential methyla-
tion related to smoking.
It is possible that differences in methyla-
tion may exist in more refined subclassifica-
tions of cell types that we did not specifically 
examine. But again, our top finding for AHRR 
cg05575921 due to maternal smoking was 
also reported in adult smokers in two different 
cell types—alveolar lung macrophage DNA 
and lymphoblast DNA (Monick et al. 2012). 
These various lines of evidence give strong 
support for the conclusion that our replicated 
findings are not explained by effects of mater-
nal smoking on the relative prevalence of white 
blood cell subtypes that differ with regard to 
CpG methyla tion.
Conclusions
In utero exposure to maternal smoking is an 
important risk factor for numerous adverse 
outcomes in children and adults. With a 
hypothesis-free epigenome-wide screen 
with replication in a second population, 
we observed strong evidence that maternal 
smoking during pregnancy is associated with 
cord blood methyla tion of genes in the AhR 
signaling pathway—important for the detoxi-
fication of xenobiotics in tobacco smoke—and 
methyla tion of a novel gene not previously 
implicated in response to tobacco smoke that 
is involved in fundamental developmental 
processes. These results suggest that epigenetic 
mechanisms reflected by DNA methyla tion 
may underlie some of the well-documented 
impacts of maternal smoking on offspring. 
Our identification of differential methyla tion 
in genes known to be involved in the response 
to tobacco-related compounds, in addition 
to a novel gene, demonstrates the value of 
using this approach to elucidate the epigenetic 
effects of in utero exposures.
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ERRATUM
Environmental Health Perspectives • ERRATUM 
NOTE: Joubert et al. [Environ Health Perspect 120:1425–1431 (2012)] have reported errors in their paper, “450K Epigenome-Wide Scan 
Identifies Differential DNA Methylation in Newborns Related to Maternal Smoking During Pregnancy.” In Figure 2, the gene name for 
the last CpG listed, cg12477880, should have been RUNX1 instead of CYP1A1. In Table 3, the percent differences in median methylation 
(smokers – nonsmokers) were incorrect for two CpGs; the correct values are –1.2 (MoBa) and –1.1 (NEST) for TTC7B cg18655025, and 
–1.8 (MoBa) and –0.3 (NEST) for HLA-DPB2 cg11715943. These values are presented correctly in Figure 2. 
EHP and the authors regret the errors.
These error have been corrected in the PDF version of this article.
